Clinical Trial: The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy

Brief Summary: The purpose of this study is to gain further insights into the molecular pathogenesis of Fuchs' endothelial corneal dystrophy (FECD), to identify targets for potential specific drug therapy.

Detailed Summary:
Sponsor: Universitaire Ziekenhuizen Leuven

Current Primary Outcome:

• cytokine levels [ Time Frame: at time of prelevation (once, no intervention) ]
  dosage of cytokine levels in aqueous humour (exploratory, non-interventional study)
• gene expression levels [ Time Frame: at time of prelevation (once, no intervention) ]
  microarray expression analysis, reverse transcriptase - quantitative polymerase chain reaction (RT-qPCR), RNA-sequencing (exploratory, non-interventional study)
• protein content [ Time Frame: at time of prelevation (once, no intervention) ]
  immunohistochemistry and immunofluorescence

Original Primary Outcome:

• cytokine levels [ Time Frame: "Day 1": at the moment of therapeutic DSAEK (for FECD patients) or at the moment of therapeutic cataract surgery (for normal controls) (during period 2014-2016) ]
  dosage of cytokine level in aqueous humour
• threefold significantly over- or underexpressed genes [ Time Frame: "Day 1": at the moment of therapeutic DSAEK (for FECD patients) or in residual material of donor corneas after therapeutic use (normal control) (during period 2012-2014) ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Universitaire Ziekenhuizen Leuven

Dates:
Date Received: January 30, 2013
Date Started: October 2012
Date Completion: September 2017
Last Updated: May 30, 2016
Last Verified: December 2015